B. Coiffier ET AL: "Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab", Clinical Cancer Research, vol. 19, no. 9, 2 April 2013 (2013-04-02), pages 2551-2561, XP055174935, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-3069 (B1)

C. STEIDL ET AL: "Macrophages predict treatment outcome in Hodgkin's lymphoma", HAEMATOLOGICA, vol. 96, no. 2, 31 January 2011 (2011-01-31), pages 186-189, XP55041473, ISSN: 0390-6078, DOI: 10.3324/haematol.2010.033316 (B1)

CHRISTIAN STEIDL ET AL: "Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma", NEW ENGLAND JOURNAL OF MEDICINE, vol. 362, no. 10, 11 March 2010 (2010-03-11), pages 875-885, XP55041466, ISSN: 0028-4793, DOI: 10.1056/NEJMoa0905680 (B1)

COIFFIER BERTRAND ET AL: 'Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study', [Online] vol. 118, no. 21, 13 December 2011, page 122, XP008157330 ISSN: 0006-4971 BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US Retrieved from the Internet: <URL:http://www.bloodjournal.org/> (B1)

D. CANIONI ET AL: "High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial", JOURNAL OF CLINICAL ONCOLOGY, vol. 26, no. 3, 20 January 2008 (2008-01-20), pages 440-446, XP55029717, ISSN: 0732-183X, DOI: 10.1200/JCO.2007.12.8298 (B1)

D. DE JONG ET AL: "Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols", HAEMATOLOGICA, vol. 94, no. 1, 1 January 2009 (2009-01-01), pages 70-77, XP55041470, ISSN: 0390-6078, DOI: 10.3324/haematol.13574 (B1)

RICCI DEBORAH S ET AL: "Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Multiple Myeloma", BLOOD; 51ST ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 05 -08, 2009, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 22, 20 November 2009 (2009-11-20), page 1491, XP008124894, ISSN: 0006-4971 (B1)

DING L ET AL: "Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 33, no. 9, 1 September 2009 (2009-09-01), pages e170-e172, XP026222057, ISSN: 0145-2126, DOI: 10.1016/J.LEUKRES.2009.03.036 [retrieved on 2009-04-28] (B1)

K. A. BLUM: "Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma", HEMATOLOGY, vol. 2010, no. 1, 1 December 2010 (2010-12-01), pages 93-100, XP55049366, ISSN: 1520-4391, DOI: 10.1182/asheducation-2010.1.93 (B1)

M. TASKINEN ET AL: "A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-P rednisone", CLINICAL CANCER RESEARCH, vol. 13, no. 19, 1 October 2007 (2007-10-01), pages 5784-5789, XP55029715, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-0778 (B1)

Mary Kay Barton: "Predictive biomarkers may help individualize treatment for patients with follicular lymphoma", CA: A Cancer Journal for Clinicians, vol. 63, no. 5, 10 July 2013 (2013-07-10), pages 293-294, XP055174933, ISSN: 0007-9235, DOI: 10.3322/caac.21197 (B1)

P. FARINHA: "Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)", BLOOD, vol. 106, no. 6, 15 September 2005 (2005-09-15), pages 2169-2174, XP55041472, ISSN: 0006-4971, DOI: 10.1182/blood-2005-04-1565 (B1)

P. KAMPER ET AL: "Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma", HAEMATOLOGICA, vol. 96, no. 2, 11 November 2010 (2010-11-11), pages 269-276, XP55041465, ISSN: 0390-6078, DOI: 10.3324/haematol.2010.031542 (B1)

DAVID P. STEENSMA ET AL: "Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome", LEUKEMIA RESEARCH, vol. 27, no. 9, 1 September 2003 (2003-09-01), pages 775-782, XP55041467, ISSN: 0145-2126, DOI: 10.1016/S0145-2126(03)00006-7 (B1)